William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating on August 13.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight the potential of Arcturus Therapeutics. The upcoming interim Phase II data for ARCT-032, an innovative inhaled mRNA therapeutic for cystic fibrosis, is a significant catalyst. The data, expected in September, could reveal promising results, especially given the substantial unmet medical need among patients with class I mutations and those who do not respond well to existing therapies.
Minter is optimistic about the financial prospects of ARCT-032, projecting it as a billion-dollar opportunity within the cystic fibrosis market. This projection is supported by the comparison to Vertex’s CFTR modulator franchise, which achieved substantial sales, suggesting that Arcturus could capture a significant market share. Additionally, 2025 is anticipated to be a transformative year for Arcturus, as it aims to expand beyond its current offerings and establish its mRNA-based platforms as commercially viable, further justifying the Buy rating.
In another report released on August 13, Canaccord Genuity also maintained a Buy rating on the stock with a $66.00 price target.